<?xml version="1.0" encoding="UTF-8"?>
<p>The study using AAV-Spark100-FIX-Padua at 5 × 10 
 <sup>11</sup> vg/kg resulted in sustained therapeutic levels of FIX of approximately 30% 
 <sup>
  <xref rid="ref-128" ref-type="bibr">128</xref>
 </sup>. Immune responses triggered by AAV capsid occurred in only two out of 10 subjects. In contrast, in the study using AAV-8-FIX-WT at 2 × 10 
 <sup>12</sup> vg/kg (fourfold higher dose), four out of six subjects developed these immune responses 
 <sup>
  <xref rid="ref-99" ref-type="bibr">99</xref>
 </sup>. Thus, the use of a transgene with enhanced biological activity allows an effective and safe strategy by minimizing vector-mediated cellular responses. This is also attractive since the AAV-5 trials showed that there is a dose-dependent elevation of the liver enzymes; thus, lowering the therapeutic dose would likely benefit all future studies.
</p>
